A new drug in clinical trial has shown promising results in treating episodic migraine.
The drug, atogepant, which is founded and developed by Allergen Plc, has met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.
Atogepant belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP).
Last month, the U.S. Food and Drug Administration approved Amgen Inc’s CGRP treatment Aimovig, which is self injected monthly and will have a list price of $6,900 a year, or $575 a month. Allergen aims to bring the first oral CGRP to the market.
Migraine is more than just a headache. It can be a debilitating condition which has a considerable impact on the quality of life of sufferers and their families. Attacks can be completely disabling, forcing the sufferer to abandon everyday activities for up to 3 days. Even in symptom-free periods, sufferers may live in fear of the next attack.